Comparative Pharmacology
Head-to-head clinical analysis: LIMBITROL DS versus LORAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIMBITROL DS versus LORAZEPAM.
LIMBITROL DS vs LORAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Limbitrol DS is a combination of amitriptyline (a tricyclic antidepressant) and chlordiazepoxide (a benzodiazepine). Amitriptyline inhibits the reuptake of serotonin and norepinephrine, enhancing neurotransmission in the CNS. Chlordiazepoxide binds to GABA-A receptors, potentiating GABAergic inhibitory effects, leading to anxiolytic and sedative effects.
Benzodiazepine that enhances GABA-A receptor activity by increasing frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
1 tablet (amitriptyline 25 mg/chlordiazepoxide 10 mg) orally 3 times daily initially, gradually increasing to 2 tablets orally 3 times daily or 3 tablets orally twice daily if needed; maximum 6 tablets per day.
2-3 mg orally or IV, 3-4 times daily; maximum 10 mg/day. For anxiety, 0.5-2 mg orally 2-3 times daily. For procedural sedation, IV: 0.044 mg/kg or 2 mg total, may repeat.
None Documented
None Documented
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateLorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."
Clinical Note
moderateLorazepam + Clemastine
Chlordiazepoxide: 5-30 hours (parent drug), active metabolite (desmethylchlordiazepoxide) 10-30 hours; amitriptyline: 13-36 hours (parent), nortriptyline (active metabolite) 18-44 hours. Half-lives increase with age and hepatic impairment.
Terminal elimination half-life is 12-18 hours. Clinically significant for once-daily dosing; may accumulate in elderly or hepatic impairment.
Renal: 70-80% as conjugated metabolites, <5% unchanged; fecal: 10-20% via biliary excretion.
Primarily renal excretion as glucuronide conjugates; less than 1% excreted unchanged. Approximately 60-80% eliminated in urine, with 15-20% in feces.
Category C
Category D/X
Benzodiazepine/Tricyclic Antidepressant Combination
Benzodiazepine
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Clemastine."